Physician profile
Arvind Kumar
NPI 1508882325
$4,198.63
in general payments reported to CMS, 2019-2025
33 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $95.82 · 2021: $315 · 2022: $775 · 2023: $950 · 2024: $662 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,558.31 | 2019-2025 | |
| Pfizer INC. | $350.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.02 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $202.92 | 2022-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $181.21 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $147.92 | 2019-2023 | Rebyota |
| Gilead Sciences, INC. | $145.61 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $143.38 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.65 | 2021-2023 | Xifaxan |
| Celgene Corporation | $115.79 | 2021-2023 | Zeposia |
| Mallinckrodt Hospital Products INC. | $89.27 | 2025 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $85.65 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $84.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $79.27 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $73.29 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $65.53 | 2024-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $61.18 | 2022-2025 | General - Hemostasis |
| Phathom Pharmaceuticals, INC. | $56.04 | 2024-2025 | Voquezna |
| Genzyme Corporation | $41.65 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.96 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $37.78 | 2020-2021 | |
| Ardelyx, INC. | $37.10 | 2022-2023 | Ibsrela |
| Allergan, INC. | $36.59 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.17 | 2023-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $34.74 | 2019-2021 | |
| Medtronic, INC. | $28.82 | 2022-2023 | Gi Genius |
| Braintree Laboratories, INC. | $24.28 | 2020-2021 | |
| Intra-Sana Laboratories | $22.22 | 2021-2022 | |
| Lilly USA, LLC | $18.03 | 2025 | Omvoh |
| Janssen Pharmaceuticals, INC | $17.86 | 2019 | |
| Olympus America INC. | $15.65 | 2025 | Visiglide |
| Fresenius Kabi USA, LLC | $13.77 | 2023 | Idacio |
| Ucb, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.